Pd-Catalyzed Enantioselective Aerobic Oxidation of Secondary Alcohols: Applications to the Total Synthesis of Alkaloids
作者:Shyam Krishnan、Jeffrey T. Bagdanoff、David C. Ebner、Yeeman K. Ramtohul、Uttam K. Tambar、Brian M. Stoltz
DOI:10.1021/ja804738b
日期:2008.10.15
Enantioselective syntheses of the alkaloids (-)-aurantioclavine, (+)-amurensinine, (-)-lobeline, and (-)- and (+)-sedamine are described. The syntheses demonstrate the effectiveness of the Pd-catalyzed asymmetric oxidation of secondary alcohols in diverse contexts and the ability of this methodology to set the absoluteconfiguration of multiple stereocenters in a single operation. The utility of an
Indirect Trapping of the Retroconjugate Addition Reaction Intermediate Involved in the Epimerization of Lobeline: Application to the Synthesis of (−)-Sedamine
作者:Guangrong Zheng、Linda P. Dwoskin、Peter A. Crooks
DOI:10.1021/jo048848j
日期:2004.11.1
Alkyl chloroformates induced indirect trapping of the retroconjugate addition reaction intermediate involved in the epimerization of lobeline is described. This strategy was applied to the conversion of (−)-lobeline to (−)-sedamine in high overall yield.
Enantioselective Access to <i>Lobelia</i> Alkaloids
作者:Delphine Compère、Christian Marazano、Bhupesh C. Das
DOI:10.1021/jo981912a
日期:1999.6.1
USE OF LOBELINE EPIMERS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES, PATHOLOGIES, AND DRUG ABUSE
申请人:Yaupon Therapeutics, Inc.
公开号:EP2217236A1
公开(公告)日:2010-08-18
Use of Lobeline Epimers in the Treatment of Central Nervous System Diseases, Pathologies, and Drug Abuse
申请人:Crooks Peter A.
公开号:US20090118331A1
公开(公告)日:2009-05-07
Methods of delivering or administering stabilized formulations or compositions having predetermined ratios, or range of ratios, of constituent epimers to an individual or a mammal for treatment of central nervous system diseases, pathologies, and drug abuse and compositions for stabilizing the compositions. In one embodiment, the predetermined ratios of constituent epimers, or range of ratios, are predetermined ratios of 2-[6S-(2S-hydroxy-2-phenyl-ethyl)-1-methyl-piperidin-2R-yl]-1-phenyl-ethanone (2R-lobeline) and its epimer, 2-[6S-(2S-hydroxy-2-phenyl-ethyl)-1-methyl-piperidin-2S-yl]-1-phenyl-ethanone (2S-lobeline). In embodiments, the stabilized formulations or compositions of 2R- and 2S-lobeline are provided in the ranges between 1 part 2R-lobeline to 10000 parts 2S-lobeline to 10000 parts 2R-lobeline to 1 part 2S-lobeline, or in the range of a 1 to 1 mixture of 2R- and 2S-lobeline, so that the predetermined epimeric ratio of 2R- and 2S-lobeline is delivered or administered to the blood, plasma or tissues of a patient so treated.